Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Pregnant women with COVID-19: new study tracks antibodies in moms and newborns

NCT ID NCT04659759

First seen Dec 10, 2025 · Last updated Jun 22, 2026 · Updated 26 times

Summary

This completed study followed 105 pregnant women who had COVID-19 or received a COVID-19 vaccine. Researchers measured antibodies in the mothers' blood and breast milk, as well as in the umbilical cord blood at delivery, to see how immunity transfers to the baby. The goal was to better understand protection for both mother and newborn up to 6 weeks after birth.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania, 19107, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this study could help doctors understand how COVID-19 antibodies pass from mother to baby and how long protection lasts after infection or vaccination.

What could go wrong

This is an observational study, not a treatment trial. It cannot prove whether vaccination or infection prevents illness in babies, and results may not apply to other populations.

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.